Predictive Oncology Inc (POAI) FinancialsPOAIFinancialPredictive Oncology Inc

Predictive Oncology Inc (POAI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Eagan, accounting for 96.2% of total sales, equivalent to $403.78K. Other significant revenue streams include Birmingham and Pittsburgh . Understanding this composition is critical for investors evaluating how POAI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Predictive Oncology Inc maintains a gross margin of -130.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -90654.06%, while the net margin is -2146123.19%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively POAI converts its operational activities into shareholder value.

In the context of the broader market, POAI competes directly with industry leaders such as EKSO and SINT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, POAI's gross margin of -130.96% stands against EKSO's N/A and SINT's 37.89%. Such benchmarking helps identify whether Predictive Oncology Inc is trading at a premium or discount relative to its financial performance.